[CAS NO. 63527-52-6] Cefotaxime
PRODUCTS SPECIFICATIONS [63527-52-6]
DESCRIPTION [63527-52-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 455.47 |
| Molecular Formula | C16H17N5O7S2 |
| SMILES | O=C(C(N12)=C(COC(C)=O)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O |
Summary
Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic , possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria [1] [2] [3] [4] [2] .
IC50 & Target
|
β-lactam |
In Vitro
Cefotaxime exhibits an MIC of 0.0625 mg/L for
V. vulnificus
CMCP6
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The combination of ciprofloxacin and cefotaxime is more effective in clearing
V. vulnificus
in vivo than previously used regimens
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female, specific pathogen free, 8-week-old BALB/c mice [4] . |
| Dosage: | 30 mg/kg. |
| Administration: | IP every 6 h. |
| Result: | The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each). |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03903783 | Groupe Hospitalier Paris Saint Joseph |
Infection, Bacterial
|
April 30, 2019 | Not Applicable |
| NCT05426499 | Poznan University of Medical Sciences|University at Buffalo|The Greater Poland Cancer Centre |
Population Modeling of Anti-infective Drugs
|
October 1, 2021 | |
| NCT02659033 | Assistance Publique - Hôpitaux de Paris |
Emergence of Bacterial Resistance to Antibiotics
|
March 2016 | Phase 3 |
| NCT00187655 | University of California, San Francisco |
Focus Groups
|
January 2004 | Phase 1 |
| NCT00469430 | Göteborg University |
Appendicitis
|
May 2006 | Phase 2 |
| NCT03198819 | Yuzuncu Y?l University |
Postoperative Infection Rates
|
August 2016 | |
| NCT04168099 | Tanta University |
Spontaneous Bacterial Peritonitis
|
December 1, 2018 | Phase 3 |
| NCT02388035 | Dr Ahmed Ali Elbaz|Nasser Institute For Research and Treatment |
Spontaneous Bacterial Peritonitis
|
March 2015 | Not Applicable |
| NCT01820026 | University of Roma La Sapienza |
Cirrhosis
|
December 2012 | Phase 4 |
| NCT02560207 | University Medical Center Groningen |
Critically Ill
|
November 2015 | Phase 4 |
| NCT05427747 | Assiut University |
Spontaneous Bacterial Peritonitis
|
January 1, 2023 | Phase 4 |
| NCT02959957 | Håkan Hanberger|Public Health Agency of Sweden |
Urinary Tract Infections
|
May 20, 2016 | Phase 4 |
| NCT01059890 | Poitiers University Hospital |
Bacterial Infection|Brain Injury
|
September 2009 | Phase 1 |
| NCT04839653 | MEDSI Clinical Hospital 1, ICU |
Pneumonia, Ventilator-Associated|Pneumonia|Bloodstream Infection|Sepsis|Respiratory Distress Syndrome|Respiratory Tract Infections|Critical Illness
|
May 1, 2021 | Not Applicable |
| NCT01551394 | PENTA Foundation|Chiesi Farmaceutici S.p.A. |
Sepsis
|
September 2012 | Phase 3 |
| NCT01265173 | Korea University |
SBP|Liver Cirrhosis
|
April 2007 | Phase 4 |
| NCT02443285 | Tanta University |
Primary Bacterial Peritonitis
|
January 2015 | Phase 3 |
| NCT03922919 | Centre Hospitalier Universitaire de Besancon |
Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)
|
April 3, 2018 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 548.88 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1955 mL | 10.9777 mL | 21.9553 mL |
| 5 mM | 0.4391 mL | 2.1955 mL | 4.3911 mL |
| 10 mM | 0.2196 mL | 1.0978 mL | 2.1955 mL |
References
- [1] Hee-Chang Jang, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014 Jun 30;9(6):e101118.
- [2] Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9.
- [3] Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7.
- [4] Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9.
- [5] E L Francke, et al. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Am J Med. 1981 Sep;71(3):435-42.
Synonyms